侨鑫余文乐的个人主页 - 老虎社区

侨鑫余文乐

暂无个人介绍

IP属地：北京

58关注

0粉丝

0主题

0勋章

侨鑫余文乐

2020-06-22

$蔚来(NIO)$看不懂，求大神指导

侨鑫余文乐

2020-06-26

$声网(API)$45第一时间卖出，不知道会不会后悔

侨鑫余文乐

2020-06-12

$燃石医学(BNR)$咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了

侨鑫余文乐

2020-06-26

$1558.SPO(1558.SPO)$如何卖出去？

侨鑫余文乐

2020-06-23

$蚬壳电业(02381)$这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪] 坑爹的，一路向下

侨鑫余文乐

2020-06-17

$东阳光药(01558)$这个除权咋操作？卖不出去，有没有大佬指点下

侨鑫余文乐

2020-10-12

$名创优品(MNSO)$大佬们，怎么看？

侨鑫余文乐

2020-09-14

真特么的醉了

获吉利德高溢价收购，Immunomedics盘前涨107%

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3479095422433274","uuid":"3479095422433274","gmtCreate":1516001401210,"gmtModify":1516001401210,"name":"侨鑫余文乐","pinyin":"qxywlqiaoxinyuwenle","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":"https://static.tigerbbs.com/e6295840391b9cdc17115677ba51429c","hatId":"tiger_head_frame","hatName":"小虎头像框","vip":1,"status":2,"fanSize":0,"headSize":58,"tweetSize":8,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.25","exceedPercentage":"93.15%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":309011472,"gmtCreate":1602493431096,"gmtModify":1703826704331,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNSO\">$名创优品(MNSO)$</a>大佬们，怎么看？","listText":"<a href=\"https://laohu8.com/S/MNSO\">$名创优品(MNSO)$</a>大佬们，怎么看？","text":"$名创优品(MNSO)$大佬们，怎么看？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/309011472","isVote":1,"tweetType":1,"viewCount":2306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":972914814,"gmtCreate":1600073134638,"gmtModify":1703820199077,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"真特么的醉了","listText":"真特么的醉了","text":"真特么的醉了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/972914814","repostId":"1101015825","repostType":4,"repost":{"id":"1101015825","kind":"news","pubTimestamp":1600072215,"share":"https://www.laohu8.com/m/news/1101015825?lang=&edition=full","pubTime":"2020-09-14 16:30","market":"us","language":"zh","title":"获吉利德高溢价收购，Immunomedics盘前涨107%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101015825","media":"美港电讯","summary":"吉利德科学溢价108%收购的这家制药公司到底有何背景？","content":"<p>9月14日盘前，生物制药公司<a href=\"https://laohu8.com/S/IMMU\">Immunomedics</a>盘前涨107%，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？</p><p><img src=\"https://static.tigerbbs.com/3f90d2252961e165e787c1f09fb0c3d1\" tg-width=\"900\" tg-height=\"559\"></p><p><b>收购Immunomedics 吉利德意在扩展肿瘤学产品组合</b></p><p>先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于1987年，总部位于加州旧金山湾区的<a href=\"https://laohu8.com/S/603806\">福斯特</a>城。主要生产和研发针对艾滋病、乙型肝炎、丙型肝炎和各类传染病的药物。</p><p><img src=\"https://static.tigerbbs.com/725970275a7818383356f61a7dbb7038\" tg-width=\"550\" tg-height=\"353\"></p><p>与Immunomedics的交易为吉利德(GILD)提供了一种治疗晚期三阴性乳腺癌的抗体药物Trodelvy，该药已于4月获得FDA加速批准。据悉，吉利德将以每股88美元的现金收购Immunomedics，比上周五收盘时的42.25每股美元超出一倍。</p><blockquote>《华尔街日报》称，吉利德支付的108%的高溢价显示了癌症药物业务的价值。</blockquote><p><b>\"此次收购代表着吉利德在建立强大而多样化的肿瘤学产品组合方面取得重大进展，\"</b>吉利德董事长兼首席执行官Daniel O'Day在一份声明中表示。\"Trodelvy已经获批以用于治疗一种特别难以治愈的癌症。我们现在将继续探索其治疗许多其他类型癌症的潜力，既可进行单药化疗，也可以与其他治疗方法联合使用。\"</p><p>O'Day在接受采访时表示，FDA在春季批准Trodelvy后，吉利德就开始与Immunomedics洽谈合作关系。他说，吉利德是参与与Immunomedics谈判的几家公司之一。此外，他补充道，在过去的两周里，谈判变为了彻底的收购，因为两家公司意识到，如果该药物只归属于一家公司，便可以更好地实现该药物的全部潜力。</p><p><b>根据两家公司的洽谈内容，这笔交易预计将在2020年第四季度完成。吉利德表示，这笔交易将由150亿美元的手头现金和大约60亿美元的新发行债务供资。</b></p><p>据悉，拉扎德和<a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>为吉利德提供咨询，而森特尔维尤合伙公司和美银美林为总部位于新泽西州的Immunomedics提供问询服务。</p><p><b>吉利德投资之路坎坷不断</b></p><p>由于其畅销的丙型肝炎治疗药物销量的下滑，吉利德近几年来一直在努力拓展肿瘤领域。2017年，吉利德斥资119亿美元收购了CAR-T癌症疗法Yescarta的制造商Kite Pharma。<b>但该疗法并没有出现分析师所希望的那种出色的销售业绩，开局不利增加了吉利德寻找有效癌症疗法的压力。</b></p><p>吉利德一直专注于利用免疫系统以对抗肿瘤的药物。今年早些时候，吉利德为制药商Forty Seven及其实验性免疫治疗药物magrolimab斥资约49亿美元，还与包括<a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a>和<a href=\"https://laohu8.com/S/JNCE\">Jounce Therapeutics Inc.</a>在内的公司签订了协议，这些公司也在研究实验性的免疫肿瘤治疗。</p><p>总部位于加利福尼亚州福斯特市的吉利德公司今年因为其抗病毒疗法remdesivir而备受关注，这是第一个获得治疗新冠病毒许可的药物。市场对该药的积极反响使吉利德股价在春天飙升。6月，据报道，吉利德正在与英国制药商<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司(AstraZeneca Plc)进行合并谈判。</p><p>然而，从那时起，投资者的热情开始消退。<b>8月份，美国监管机构未能批准其与比利时生物技术公司<a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a>合作开发的一种类风湿性关节炎治疗方法，吉利德遭受打击，而投资者对remdesivir的商业潜力也变得不那么自信。</b></p><p>周五收盘时，吉利德股价年初至今上涨约1%，报65.580美元，该公司市值为822亿美元。</p><p><img src=\"https://static.tigerbbs.com/7880913fd04390e3b6799c2814dd0e5a\" tg-width=\"840\" tg-height=\"470\"></p><p><b>未来增长动力加强 吉利德或绝地反击</b></p><p><b>收购Immunomedics后，吉利德在治疗乳腺癌等肿瘤疾病的巨大药物市场中将会产生立竿见影的改变，并与Yescarta等专注于血液肿瘤的药物形成互补。</b></p><p>\"对吉利德来说，这个时刻至关重要。它使我们能够在病毒学之外为公司提供一个更加清晰的增长轮廓，\"O'Day说。\"这绝对是未来的增长动力。\"</p><p><b>O'Day表示，\"可以非常肯定地说\"，该药物具有数十亿美元的销售额潜力。</b></p><p>吉利德的报价不受融资条件限制，将以约150亿美元现金和约60亿美元新发行的债务进行融资。预计该交易将不会改变吉利德2023年的调整后EPS，但此后将使盈利上升。</p><p><b>据介绍，Immunomedics, Inc.是一家临床阶段生物制药公司。该公司致力于开发基于单克隆抗体用于癌症靶向治疗的产品。</b>该公司技术使其能够产生人源化抗体，可单独以未标记或裸露形式使用，或与放射性同位素、化学治疗剂、细胞因子或毒素结合使用。该公司拥有六个临床阶段候选产品。其研究产品组合包括抗体偶联药物（ADC），用于将有效载荷的化学治疗剂直接递送至肿瘤并同时管理在常规施用化学治疗剂时产生的总体毒性作用。该公司的ADC包括sacituzumab govitecan（IMMU-132）和labetuzumab govitecan（IMMU-130）。该公司还拥有一系列处于临床和临床前开发阶段针对实体肿瘤、恶性血液病以及其他疾病的其他候选产品。</p>","source":"live_meigang","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>获吉利德高溢价收购，Immunomedics盘前涨107%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n获吉利德高溢价收购，Immunomedics盘前涨107%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-09-14 16:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://news.ushknews.com/mobile/details.html?id=1000839><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月14日盘前，生物制药公司Immunomedics盘前涨107%，吉利德科学将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？收购Immunomedics 吉利德意在扩展肿瘤学产品组合先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于...</p>\n\n<a href=\"https://news.ushknews.com/mobile/details.html?id=1000839\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/397ea9f4c5ed7181ce32544a12b4b083","relate_stocks":{"IMMU":"Immunomedics","GILD":"吉利德科学"},"source_url":"https://news.ushknews.com/mobile/details.html?id=1000839","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101015825","content_text":"9月14日盘前，生物制药公司Immunomedics盘前涨107%，吉利德科学将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？收购Immunomedics 吉利德意在扩展肿瘤学产品组合先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于1987年，总部位于加州旧金山湾区的福斯特城。主要生产和研发针对艾滋病、乙型肝炎、丙型肝炎和各类传染病的药物。与Immunomedics的交易为吉利德(GILD)提供了一种治疗晚期三阴性乳腺癌的抗体药物Trodelvy，该药已于4月获得FDA加速批准。据悉，吉利德将以每股88美元的现金收购Immunomedics，比上周五收盘时的42.25每股美元超出一倍。《华尔街日报》称，吉利德支付的108%的高溢价显示了癌症药物业务的价值。\"此次收购代表着吉利德在建立强大而多样化的肿瘤学产品组合方面取得重大进展，\"吉利德董事长兼首席执行官Daniel O'Day在一份声明中表示。\"Trodelvy已经获批以用于治疗一种特别难以治愈的癌症。我们现在将继续探索其治疗许多其他类型癌症的潜力，既可进行单药化疗，也可以与其他治疗方法联合使用。\"O'Day在接受采访时表示，FDA在春季批准Trodelvy后，吉利德就开始与Immunomedics洽谈合作关系。他说，吉利德是参与与Immunomedics谈判的几家公司之一。此外，他补充道，在过去的两周里，谈判变为了彻底的收购，因为两家公司意识到，如果该药物只归属于一家公司，便可以更好地实现该药物的全部潜力。根据两家公司的洽谈内容，这笔交易预计将在2020年第四季度完成。吉利德表示，这笔交易将由150亿美元的手头现金和大约60亿美元的新发行债务供资。据悉，拉扎德和摩根士丹利为吉利德提供咨询，而森特尔维尤合伙公司和美银美林为总部位于新泽西州的Immunomedics提供问询服务。吉利德投资之路坎坷不断由于其畅销的丙型肝炎治疗药物销量的下滑，吉利德近几年来一直在努力拓展肿瘤领域。2017年，吉利德斥资119亿美元收购了CAR-T癌症疗法Yescarta的制造商Kite Pharma。但该疗法并没有出现分析师所希望的那种出色的销售业绩，开局不利增加了吉利德寻找有效癌症疗法的压力。吉利德一直专注于利用免疫系统以对抗肿瘤的药物。今年早些时候，吉利德为制药商Forty Seven及其实验性免疫治疗药物magrolimab斥资约49亿美元，还与包括Arcus Biosciences Inc.和Jounce Therapeutics Inc.在内的公司签订了协议，这些公司也在研究实验性的免疫肿瘤治疗。总部位于加利福尼亚州福斯特市的吉利德公司今年因为其抗病毒疗法remdesivir而备受关注，这是第一个获得治疗新冠病毒许可的药物。市场对该药的积极反响使吉利德股价在春天飙升。6月，据报道，吉利德正在与英国制药商阿斯利康公司(AstraZeneca Plc)进行合并谈判。然而，从那时起，投资者的热情开始消退。8月份，美国监管机构未能批准其与比利时生物技术公司Galapagos NV合作开发的一种类风湿性关节炎治疗方法，吉利德遭受打击，而投资者对remdesivir的商业潜力也变得不那么自信。周五收盘时，吉利德股价年初至今上涨约1%，报65.580美元，该公司市值为822亿美元。未来增长动力加强 吉利德或绝地反击收购Immunomedics后，吉利德在治疗乳腺癌等肿瘤疾病的巨大药物市场中将会产生立竿见影的改变，并与Yescarta等专注于血液肿瘤的药物形成互补。\"对吉利德来说，这个时刻至关重要。它使我们能够在病毒学之外为公司提供一个更加清晰的增长轮廓，\"O'Day说。\"这绝对是未来的增长动力。\"O'Day表示，\"可以非常肯定地说\"，该药物具有数十亿美元的销售额潜力。吉利德的报价不受融资条件限制，将以约150亿美元现金和约60亿美元新发行的债务进行融资。预计该交易将不会改变吉利德2023年的调整后EPS，但此后将使盈利上升。据介绍，Immunomedics, Inc.是一家临床阶段生物制药公司。该公司致力于开发基于单克隆抗体用于癌症靶向治疗的产品。该公司技术使其能够产生人源化抗体，可单独以未标记或裸露形式使用，或与放射性同位素、化学治疗剂、细胞因子或毒素结合使用。该公司拥有六个临床阶段候选产品。其研究产品组合包括抗体偶联药物（ADC），用于将有效载荷的化学治疗剂直接递送至肿瘤并同时管理在常规施用化学治疗剂时产生的总体毒性作用。该公司的ADC包括sacituzumab govitecan（IMMU-132）和labetuzumab govitecan（IMMU-130）。该公司还拥有一系列处于临床和临床前开发阶段针对实体肿瘤、恶性血液病以及其他疾病的其他候选产品。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":957358373,"gmtCreate":1593186243492,"gmtModify":1704201514275,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/API\">$声网(API)$</a>45第一时间卖出，不知道会不会后悔","listText":"<a href=\"https://laohu8.com/S/API\">$声网(API)$</a>45第一时间卖出，不知道会不会后悔","text":"$声网(API)$45第一时间卖出，不知道会不会后悔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/957358373","isVote":1,"tweetType":1,"viewCount":3035,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":957933382,"gmtCreate":1593152565146,"gmtModify":1704201306783,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/1558.SPO\">$1558.SPO(1558.SPO)$</a>如何卖出去？","listText":"<a href=\"https://laohu8.com/S/1558.SPO\">$1558.SPO(1558.SPO)$</a>如何卖出去？","text":"$1558.SPO(1558.SPO)$如何卖出去？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/957933382","isVote":1,"tweetType":1,"viewCount":2215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":954600496,"gmtCreate":1592893176615,"gmtModify":1704200471870,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02381\">$蚬壳电业(02381)$</a>这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪]&nbsp;坑爹的，一路向下","listText":"<a href=\"https://laohu8.com/S/02381\">$蚬壳电业(02381)$</a>这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪]&nbsp;坑爹的，一路向下","text":"$蚬壳电业(02381)$这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪] 坑爹的，一路向下","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/954600496","isVote":1,"tweetType":1,"viewCount":3306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":954366614,"gmtCreate":1592799153738,"gmtModify":1704200135073,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>看不懂，求大神指导","listText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>看不懂，求大神指导","text":"$蔚来(NIO)$看不懂，求大神指导","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":13,"repostSize":0,"link":"https://laohu8.com/post/954366614","isVote":1,"tweetType":1,"viewCount":7292,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3471437262956953","authorId":"3471437262956953","name":"瀚海阑干百丈冰","avatar":"https://static.tigerbbs.com/68c139313636c89ff6268f9734e78592","crmLevel":2,"crmLevelSwitch":0,"idStr":"3471437262956953","authorIdStr":"3471437262956953"},"content":"全仓就完事","text":"全仓就完事","html":"全仓就完事"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":955869890,"gmtCreate":1592370696510,"gmtModify":1704199030851,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01558\">$东阳光药(01558)$</a>这个除权咋操作？卖不出去，有没有大佬指点下","listText":"<a href=\"https://laohu8.com/S/01558\">$东阳光药(01558)$</a>这个除权咋操作？卖不出去，有没有大佬指点下","text":"$东阳光药(01558)$这个除权咋操作？卖不出去，有没有大佬指点下","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/955869890","isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952209751,"gmtCreate":1591971760373,"gmtModify":1704197856309,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNR\">$燃石医学(BNR)$</a>咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","listText":"<a href=\"https://laohu8.com/S/BNR\">$燃石医学(BNR)$</a>咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","text":"$燃石医学(BNR)$咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/952209751","isVote":1,"tweetType":1,"viewCount":3211,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":954366614,"gmtCreate":1592799153738,"gmtModify":1704200135073,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>看不懂，求大神指导","listText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>看不懂，求大神指导","text":"$蔚来(NIO)$看不懂，求大神指导","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":13,"repostSize":0,"link":"https://laohu8.com/post/954366614","isVote":1,"tweetType":1,"viewCount":7292,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3471437262956953","authorId":"3471437262956953","name":"瀚海阑干百丈冰","avatar":"https://static.tigerbbs.com/68c139313636c89ff6268f9734e78592","crmLevel":2,"crmLevelSwitch":0,"idStr":"3471437262956953","authorIdStr":"3471437262956953"},"content":"全仓就完事","text":"全仓就完事","html":"全仓就完事"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":957358373,"gmtCreate":1593186243492,"gmtModify":1704201514275,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/API\">$声网(API)$</a>45第一时间卖出，不知道会不会后悔","listText":"<a href=\"https://laohu8.com/S/API\">$声网(API)$</a>45第一时间卖出，不知道会不会后悔","text":"$声网(API)$45第一时间卖出，不知道会不会后悔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/957358373","isVote":1,"tweetType":1,"viewCount":3035,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952209751,"gmtCreate":1591971760373,"gmtModify":1704197856309,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNR\">$燃石医学(BNR)$</a>咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","listText":"<a href=\"https://laohu8.com/S/BNR\">$燃石医学(BNR)$</a>咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","text":"$燃石医学(BNR)$咨询个小问题，美股是不是100%中签率？虽然每次都不多，但是自从打新，5连中了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/952209751","isVote":1,"tweetType":1,"viewCount":3211,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":957933382,"gmtCreate":1593152565146,"gmtModify":1704201306783,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/1558.SPO\">$1558.SPO(1558.SPO)$</a>如何卖出去？","listText":"<a href=\"https://laohu8.com/S/1558.SPO\">$1558.SPO(1558.SPO)$</a>如何卖出去？","text":"$1558.SPO(1558.SPO)$如何卖出去？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/957933382","isVote":1,"tweetType":1,"viewCount":2215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":954600496,"gmtCreate":1592893176615,"gmtModify":1704200471870,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02381\">$蚬壳电业(02381)$</a>这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪]&nbsp;坑爹的，一路向下","listText":"<a href=\"https://laohu8.com/S/02381\">$蚬壳电业(02381)$</a>这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪]&nbsp;坑爹的，一路向下","text":"$蚬壳电业(02381)$这个垃圾股还有拿着的必要么？中完签一直在兜里放着，就没有翻一下的可能了么[流泪] 坑爹的，一路向下","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/954600496","isVote":1,"tweetType":1,"viewCount":3306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":955869890,"gmtCreate":1592370696510,"gmtModify":1704199030851,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01558\">$东阳光药(01558)$</a>这个除权咋操作？卖不出去，有没有大佬指点下","listText":"<a href=\"https://laohu8.com/S/01558\">$东阳光药(01558)$</a>这个除权咋操作？卖不出去，有没有大佬指点下","text":"$东阳光药(01558)$这个除权咋操作？卖不出去，有没有大佬指点下","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/955869890","isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309011472,"gmtCreate":1602493431096,"gmtModify":1703826704331,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNSO\">$名创优品(MNSO)$</a>大佬们，怎么看？","listText":"<a href=\"https://laohu8.com/S/MNSO\">$名创优品(MNSO)$</a>大佬们，怎么看？","text":"$名创优品(MNSO)$大佬们，怎么看？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/309011472","isVote":1,"tweetType":1,"viewCount":2306,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":972914814,"gmtCreate":1600073134638,"gmtModify":1703820199077,"author":{"id":"3479095422433274","authorId":"3479095422433274","name":"侨鑫余文乐","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3479095422433274","authorIdStr":"3479095422433274"},"themes":[],"htmlText":"真特么的醉了","listText":"真特么的醉了","text":"真特么的醉了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/972914814","repostId":"1101015825","repostType":4,"repost":{"id":"1101015825","kind":"news","pubTimestamp":1600072215,"share":"https://www.laohu8.com/m/news/1101015825?lang=&edition=full","pubTime":"2020-09-14 16:30","market":"us","language":"zh","title":"获吉利德高溢价收购，Immunomedics盘前涨107%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101015825","media":"美港电讯","summary":"吉利德科学溢价108%收购的这家制药公司到底有何背景？","content":"<p>9月14日盘前，生物制药公司<a href=\"https://laohu8.com/S/IMMU\">Immunomedics</a>盘前涨107%，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？</p><p><img src=\"https://static.tigerbbs.com/3f90d2252961e165e787c1f09fb0c3d1\" tg-width=\"900\" tg-height=\"559\"></p><p><b>收购Immunomedics 吉利德意在扩展肿瘤学产品组合</b></p><p>先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于1987年，总部位于加州旧金山湾区的<a href=\"https://laohu8.com/S/603806\">福斯特</a>城。主要生产和研发针对艾滋病、乙型肝炎、丙型肝炎和各类传染病的药物。</p><p><img src=\"https://static.tigerbbs.com/725970275a7818383356f61a7dbb7038\" tg-width=\"550\" tg-height=\"353\"></p><p>与Immunomedics的交易为吉利德(GILD)提供了一种治疗晚期三阴性乳腺癌的抗体药物Trodelvy，该药已于4月获得FDA加速批准。据悉，吉利德将以每股88美元的现金收购Immunomedics，比上周五收盘时的42.25每股美元超出一倍。</p><blockquote>《华尔街日报》称，吉利德支付的108%的高溢价显示了癌症药物业务的价值。</blockquote><p><b>\"此次收购代表着吉利德在建立强大而多样化的肿瘤学产品组合方面取得重大进展，\"</b>吉利德董事长兼首席执行官Daniel O'Day在一份声明中表示。\"Trodelvy已经获批以用于治疗一种特别难以治愈的癌症。我们现在将继续探索其治疗许多其他类型癌症的潜力，既可进行单药化疗，也可以与其他治疗方法联合使用。\"</p><p>O'Day在接受采访时表示，FDA在春季批准Trodelvy后，吉利德就开始与Immunomedics洽谈合作关系。他说，吉利德是参与与Immunomedics谈判的几家公司之一。此外，他补充道，在过去的两周里，谈判变为了彻底的收购，因为两家公司意识到，如果该药物只归属于一家公司，便可以更好地实现该药物的全部潜力。</p><p><b>根据两家公司的洽谈内容，这笔交易预计将在2020年第四季度完成。吉利德表示，这笔交易将由150亿美元的手头现金和大约60亿美元的新发行债务供资。</b></p><p>据悉，拉扎德和<a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>为吉利德提供咨询，而森特尔维尤合伙公司和美银美林为总部位于新泽西州的Immunomedics提供问询服务。</p><p><b>吉利德投资之路坎坷不断</b></p><p>由于其畅销的丙型肝炎治疗药物销量的下滑，吉利德近几年来一直在努力拓展肿瘤领域。2017年，吉利德斥资119亿美元收购了CAR-T癌症疗法Yescarta的制造商Kite Pharma。<b>但该疗法并没有出现分析师所希望的那种出色的销售业绩，开局不利增加了吉利德寻找有效癌症疗法的压力。</b></p><p>吉利德一直专注于利用免疫系统以对抗肿瘤的药物。今年早些时候，吉利德为制药商Forty Seven及其实验性免疫治疗药物magrolimab斥资约49亿美元，还与包括<a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences Inc.</a>和<a href=\"https://laohu8.com/S/JNCE\">Jounce Therapeutics Inc.</a>在内的公司签订了协议，这些公司也在研究实验性的免疫肿瘤治疗。</p><p>总部位于加利福尼亚州福斯特市的吉利德公司今年因为其抗病毒疗法remdesivir而备受关注，这是第一个获得治疗新冠病毒许可的药物。市场对该药的积极反响使吉利德股价在春天飙升。6月，据报道，吉利德正在与英国制药商<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>公司(AstraZeneca Plc)进行合并谈判。</p><p>然而，从那时起，投资者的热情开始消退。<b>8月份，美国监管机构未能批准其与比利时生物技术公司<a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a>合作开发的一种类风湿性关节炎治疗方法，吉利德遭受打击，而投资者对remdesivir的商业潜力也变得不那么自信。</b></p><p>周五收盘时，吉利德股价年初至今上涨约1%，报65.580美元，该公司市值为822亿美元。</p><p><img src=\"https://static.tigerbbs.com/7880913fd04390e3b6799c2814dd0e5a\" tg-width=\"840\" tg-height=\"470\"></p><p><b>未来增长动力加强 吉利德或绝地反击</b></p><p><b>收购Immunomedics后，吉利德在治疗乳腺癌等肿瘤疾病的巨大药物市场中将会产生立竿见影的改变，并与Yescarta等专注于血液肿瘤的药物形成互补。</b></p><p>\"对吉利德来说，这个时刻至关重要。它使我们能够在病毒学之外为公司提供一个更加清晰的增长轮廓，\"O'Day说。\"这绝对是未来的增长动力。\"</p><p><b>O'Day表示，\"可以非常肯定地说\"，该药物具有数十亿美元的销售额潜力。</b></p><p>吉利德的报价不受融资条件限制，将以约150亿美元现金和约60亿美元新发行的债务进行融资。预计该交易将不会改变吉利德2023年的调整后EPS，但此后将使盈利上升。</p><p><b>据介绍，Immunomedics, Inc.是一家临床阶段生物制药公司。该公司致力于开发基于单克隆抗体用于癌症靶向治疗的产品。</b>该公司技术使其能够产生人源化抗体，可单独以未标记或裸露形式使用，或与放射性同位素、化学治疗剂、细胞因子或毒素结合使用。该公司拥有六个临床阶段候选产品。其研究产品组合包括抗体偶联药物（ADC），用于将有效载荷的化学治疗剂直接递送至肿瘤并同时管理在常规施用化学治疗剂时产生的总体毒性作用。该公司的ADC包括sacituzumab govitecan（IMMU-132）和labetuzumab govitecan（IMMU-130）。该公司还拥有一系列处于临床和临床前开发阶段针对实体肿瘤、恶性血液病以及其他疾病的其他候选产品。</p>","source":"live_meigang","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>获吉利德高溢价收购，Immunomedics盘前涨107%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n获吉利德高溢价收购，Immunomedics盘前涨107%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-09-14 16:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://news.ushknews.com/mobile/details.html?id=1000839><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月14日盘前，生物制药公司Immunomedics盘前涨107%，吉利德科学将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？收购Immunomedics 吉利德意在扩展肿瘤学产品组合先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于...</p>\n\n<a href=\"https://news.ushknews.com/mobile/details.html?id=1000839\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/397ea9f4c5ed7181ce32544a12b4b083","relate_stocks":{"IMMU":"Immunomedics","GILD":"吉利德科学"},"source_url":"https://news.ushknews.com/mobile/details.html?id=1000839","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101015825","content_text":"9月14日盘前，生物制药公司Immunomedics盘前涨107%，吉利德科学将以210亿美元（每股88美元）价格收购该公司，上周五收盘时，Immunomedics股价才42美元，吉利德科学溢价108%收购的这家制药公司到底有何背景？收购Immunomedics 吉利德意在扩展肿瘤学产品组合先来介绍一下吉利德科学公司（Gilead Sciences, Inc.），一家美国大型生物制药公司，成立于1987年，总部位于加州旧金山湾区的福斯特城。主要生产和研发针对艾滋病、乙型肝炎、丙型肝炎和各类传染病的药物。与Immunomedics的交易为吉利德(GILD)提供了一种治疗晚期三阴性乳腺癌的抗体药物Trodelvy，该药已于4月获得FDA加速批准。据悉，吉利德将以每股88美元的现金收购Immunomedics，比上周五收盘时的42.25每股美元超出一倍。《华尔街日报》称，吉利德支付的108%的高溢价显示了癌症药物业务的价值。\"此次收购代表着吉利德在建立强大而多样化的肿瘤学产品组合方面取得重大进展，\"吉利德董事长兼首席执行官Daniel O'Day在一份声明中表示。\"Trodelvy已经获批以用于治疗一种特别难以治愈的癌症。我们现在将继续探索其治疗许多其他类型癌症的潜力，既可进行单药化疗，也可以与其他治疗方法联合使用。\"O'Day在接受采访时表示，FDA在春季批准Trodelvy后，吉利德就开始与Immunomedics洽谈合作关系。他说，吉利德是参与与Immunomedics谈判的几家公司之一。此外，他补充道，在过去的两周里，谈判变为了彻底的收购，因为两家公司意识到，如果该药物只归属于一家公司，便可以更好地实现该药物的全部潜力。根据两家公司的洽谈内容，这笔交易预计将在2020年第四季度完成。吉利德表示，这笔交易将由150亿美元的手头现金和大约60亿美元的新发行债务供资。据悉，拉扎德和摩根士丹利为吉利德提供咨询，而森特尔维尤合伙公司和美银美林为总部位于新泽西州的Immunomedics提供问询服务。吉利德投资之路坎坷不断由于其畅销的丙型肝炎治疗药物销量的下滑，吉利德近几年来一直在努力拓展肿瘤领域。2017年，吉利德斥资119亿美元收购了CAR-T癌症疗法Yescarta的制造商Kite Pharma。但该疗法并没有出现分析师所希望的那种出色的销售业绩，开局不利增加了吉利德寻找有效癌症疗法的压力。吉利德一直专注于利用免疫系统以对抗肿瘤的药物。今年早些时候，吉利德为制药商Forty Seven及其实验性免疫治疗药物magrolimab斥资约49亿美元，还与包括Arcus Biosciences Inc.和Jounce Therapeutics Inc.在内的公司签订了协议，这些公司也在研究实验性的免疫肿瘤治疗。总部位于加利福尼亚州福斯特市的吉利德公司今年因为其抗病毒疗法remdesivir而备受关注，这是第一个获得治疗新冠病毒许可的药物。市场对该药的积极反响使吉利德股价在春天飙升。6月，据报道，吉利德正在与英国制药商阿斯利康公司(AstraZeneca Plc)进行合并谈判。然而，从那时起，投资者的热情开始消退。8月份，美国监管机构未能批准其与比利时生物技术公司Galapagos NV合作开发的一种类风湿性关节炎治疗方法，吉利德遭受打击，而投资者对remdesivir的商业潜力也变得不那么自信。周五收盘时，吉利德股价年初至今上涨约1%，报65.580美元，该公司市值为822亿美元。未来增长动力加强 吉利德或绝地反击收购Immunomedics后，吉利德在治疗乳腺癌等肿瘤疾病的巨大药物市场中将会产生立竿见影的改变，并与Yescarta等专注于血液肿瘤的药物形成互补。\"对吉利德来说，这个时刻至关重要。它使我们能够在病毒学之外为公司提供一个更加清晰的增长轮廓，\"O'Day说。\"这绝对是未来的增长动力。\"O'Day表示，\"可以非常肯定地说\"，该药物具有数十亿美元的销售额潜力。吉利德的报价不受融资条件限制，将以约150亿美元现金和约60亿美元新发行的债务进行融资。预计该交易将不会改变吉利德2023年的调整后EPS，但此后将使盈利上升。据介绍，Immunomedics, Inc.是一家临床阶段生物制药公司。该公司致力于开发基于单克隆抗体用于癌症靶向治疗的产品。该公司技术使其能够产生人源化抗体，可单独以未标记或裸露形式使用，或与放射性同位素、化学治疗剂、细胞因子或毒素结合使用。该公司拥有六个临床阶段候选产品。其研究产品组合包括抗体偶联药物（ADC），用于将有效载荷的化学治疗剂直接递送至肿瘤并同时管理在常规施用化学治疗剂时产生的总体毒性作用。该公司的ADC包括sacituzumab govitecan（IMMU-132）和labetuzumab govitecan（IMMU-130）。该公司还拥有一系列处于临床和临床前开发阶段针对实体肿瘤、恶性血液病以及其他疾病的其他候选产品。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}